

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934**

For the Month of: December 2016

Commission File Number: 001-37847

MOTIF BIO PLC

(Exact name of Registrant as specified in its charter)

**125 Park Avenue
25th Floor, Suite 2622
New York, New York 10011**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On December 22, 2016, Motif Bio plc (the "Company") issued a press release announcing that all resolutions put to shareholders at the Company's General Meeting were duly passed, a copy of which is attached as Exhibit 99.1 to this Report on Form 6-K. On December 22, 2016, the Company also issued a press release announcing the conversion of certain convertible promissory notes, a copy of which is attached as Exhibit 99.2 to this Report on Form 6-K.

The information in this Report on Form 6-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Exhibits

Exhibit Number	Exhibit Table
99.1	Press Release issued by Motif Bio plc, dated December 22, 2016, announcing the results of the Company's General Meeting.
99.2	Press Release issued by Motif Bio plc, dated December 22, 2016, announcing the conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: December 22, 2016

MOTIF BIO PLC

By: /s/ Graham Lumsden
Graham Lumsden
Chief Executive Officer

3



21 December 2016

Motif Bio plc
 (“Motif Bio” or the “Company”)

Result of GM

Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that all resolutions put to shareholders at the Company’s General Meeting held earlier today were duly passed.

For further information please contact:

Motif Bio plc Graham Lumsden (Chief Executive Officer)	info@motifbio.com
Zeus Capital Limited (NOMAD & BROKER) Phil Walker/Giles Balleny Dominic Wilson	+44 (0)20 3829 5000
Northland Capital Partners Limited (BROKER) Patrick Claridge/ David Hignell John Howes/ Rob Rees (Broking)	+44 (0)203 861 6625
Walbrook PR Ltd. (FINANCIAL PR & IR) Paul McManus Mike Wort	+44 (0) 20 7933 8780 or motifbio@walbrookpr.com Mob: +44 (0)7980 541 893 Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN IR) Raimund Gabriel	+49 (0)89 210 2280



Motif Bio plc Announces Conversion of Convertible Promissory Notes, PDMR Dealing and Total Voting Rights

NEW YORK, December 22, 2016 (GLOBE NEWSWIRE) —Motif Bio plc (Motif)(NASDAQ: MTFB), (NASDAQ: MTFBW), a clinical stage biopharmaceutical company specializing in developing novel antibiotics announced, that it has issued, in aggregate, 14,510,770 new ordinary shares in the Company (“Ordinary Shares”) following the conversion by Amphion Innovations plc and Amphion Innovations US Inc., (the “Amphion Parties”) of the Convertible Promissory Notes (“CPNs”). The CPNs which totalled US\$3,550,786 were converted in accordance with their terms at US\$0.2447 per share.

Following the conversion, the Amphion Parties hold no further CPNs and their holdings total 43,240,645 ordinary shares, being 22% of the Company.

Application has been made for the 14,510,770 new Ordinary Shares to be admitted to trading on AIM (“Admission”), which is expected to occur on December 29, 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company’s total issued share capital will consist of 195,741,528 Ordinary Shares.

About Motif

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (REVIVE-1 and REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

For further information please contact:

Motif Bio plc Contact:
 Pete A. Meyers
 Chief Financial Officer
 212-210-6248
 ir@motifbio.com

Investor Contact:
 Patricia L. Bank
 Westwicke Partners
 415-513-1284
 patti.bank@westwicke.com



Motif BioSciences Inc.
